Clinical Trial Search

Phase 3 N=50 Efficacy and Safety of Imipenem+Cilastatin/Relebactam (MK-7655A) Versus Colistimethate Sodium+Imipenem+Cilastatin in Imipenem-Resistant Bacterial Infection (MK-7655A-013)

Bacterial Infections

Primary: Percentage of Participants With Favorable Overall Response (FOR) — 71.4; 70.0 Percentage of Participants

Merck Sharp & Dohme LLC Results Oct 2018 24.0% serious AE View details

Phase 3 N=751 Phase III Study of ASP2151 in Herpes Zoster Patients

Herpes Zoster

Primary: The Percentage of Participants Achieving Cessation of New Lesion Formation by Day 4 of Study Treatment — 69.6; 81.1; 75.1 percentage of Participants — p=0.00000241

Maruho Co., Ltd. Results Oct 2018 0.7% serious AE View details

Phase 3 N=493 Clinical Trial of Safety and Efficacy of Various Dosage Schedules for Dietressa Drug in Treatment of Obese Patients

Obesity

Primary: Percentage of Subjects Who Lose at Least 5 Percent of Baseline Body Weight After 24 Weeks of Treatment Weeks of Treatment — 49; 48; 33; 21 percentage of participants…

Materia Medica Holding Results Oct 2018 0.6% serious AE View details

Phase 3 N=422 A Study to Confirm the Efficacy and Safety of Different Dupilumab Dose Regimens in Adults With Atopic Dermatitis (AD)

Atopic Dermatitis

Primary: Difference Between Current Study Baseline and Week 36 in Percent Change in EASI From Parent Study Baseline (NCT02277743 and NCT02277769) — 21.67; 6.84; 3.84; 0.06…

Regeneron Pharmaceuticals Results Oct 2018 3.3% serious AE View details

Phase 3 N=32 Gynaecological Follow-up of a Subset of HPV-015 (NCT00294047) Study Subjects

Infections, Papillomavirus

Primary: Number of Subjects Reporting Positive Oncogenic HPV DNA Results by Hybrid Capture II Test (HCII) at Month 12 — 2 Participants

GlaxoSmithKline Results Oct 2018 0.0% serious AE View details

Phase 3 N=498 A Study of Vemurafenib Adjuvant Therapy in Participants With Surgically Resected Cutaneous BRAF-Mutant Melanoma

Melanoma

Primary: Disease-Free Survival (DFS) as Assessed Using Contrast-Enhanced Magnetic Resonance Imaging (MRI) or Contrast Enhanced Computed Tomography (CT) — NA; 36.9; 23.1; 15.4…

Hoffmann-La Roche Results Oct 2018 13.2% serious AE View details

Phase 3 N=55 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of E/C/F/TAF Fixed Dose Combination (FDC) in HIV-1 Infected Adults on Chronic Hemodialysis

HIV-1 Infection

Primary: GEN Phase: Percentage of Participants Experiencing Treatment-Emergent Grade 3 or Higher Adverse Events Up to Week 48 — 32.7 percentage of participants

Gilead Sciences Results Oct 2018 60.0% serious AE View details

Phase 3 N=401 Study to Evaluate the Impact of Reactogenicity on Quality of Life (QoL), After Administration of GlaxoSmithKline (GSK) Biologicals' Candidate Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 50 Years of Age

Herpes Zoster

Primary: Change in the Short Form 36-item-health Survey (SF36) Physical Functioning (PF) From Baseline Score to Mean Score After First Dose — 1.9 Score units

GlaxoSmithKline Results Oct 2018 3.5% serious AE View details

Phase 3 N=1,096 Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)

Advanced Renal Cell Carcinoma · Metastatic Renal Cell Carcinoma

Primary: Objective Response Rate (ORR) in Intermediate/Poor Risk Participants Per Independent Radiology Review Committee (IRRC) Using RECIST v1.1 — 41.6; 26.5 percentage of…

Bristol-Myers Squibb Results Oct 2018 58.7% serious AE View details

Phase 3 N=346 An Open-label Extension Study of Certolizumab Pegol in Chinese Patients With Rheumatoid Arthritis Who Enrolled in RA0044

Rheumatoid Arthritis

Primary: Percentage of Subjects That Withdrew Due to a Treatment-emergent Adverse Event (TEAE) — 2.1; 1.6 percentage of participants

UCB Pharma SA Results Oct 2018 3.2% serious AE View details

Phase 3 N=206 Sequential Use of Fluoxetine for Smokers With Elevated Depressive Symptoms

Major Depressive Disorder · Nicotine Dependence · Depression

Primary: Number of Participants Achieving Smoking Abstinence — 24; 18 Participants

Butler Hospital Results Oct 2018 0.0% serious AE View details

Phase 3 N=69 A Study of Plazomicin Compared With Colistin in Patients With Infection Due to Carbapenem-Resistant Enterobacteriaceae (CRE)

Bloodstream Infections (BSI) Due to CRE · Hospital-Acquired Bacterial Pneumonia (HABP) Due to CRE · Ventilator-Associated Bacterial Pneumonia (VABP) Due to CRE

Primary: Percentage of Patients With All Cause Mortality (ACM) at Day 28 or Significant Disease-Related Complication (SDRC) in the Microbiological Modified Intent to Treat…

Achaogen, Inc. Results Oct 2018 66.7% serious AE View details

Phase 3 N=169 ESSENCE Study: Efficacy and Safety of SD-101 Cream in Participants With Epidermolysis Bullosa

Epidermolysis Bullosa

Primary: Time To Complete Target Wound Closure Within 3 Months — 41.6; 53.6 days — p=0.985

Scioderm, Inc. Results Oct 2018 7.1% serious AE View details

Phase 3 N=199 Naloxone for Optimizing Hypoxemia Of Lung Donors

Brain Death · Organ Donors · Lung Transplantation

Primary: Change in Oxygenation (P/F Ratio) From Baseline to Final Pre-recovery Arterial Blood Gas (ABG) — 81; 80 mm Hg

Washington University School of Medicine Results Oct 2018 0.0% serious AE View details

Phase 3 N=59 Short Bowel Syndrome Research Study for Children Up To 17 Years of Age on Parenteral Nutrition

Short Bowel Syndrome

Primary: Number of Participants Who Achieved at Least a 20 Percent (%) Reduction in Weight-Normalized Average Daily Parenteral Nutrition Intravenous (PN/IV) Volume at Week 24…

Shire Results Oct 2018 66.1% serious AE View details